Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case study reports a rare instance of pembrolizumab-induced eyelash trichomegaly in a 63-year-old male patient, highlighting the importance for clinicians to be aware of such uncommon adverse effects to manage patient treatment effectively.

This case study highlights the importance of early detection and management of pembrolizumab-induced hepatitis, suggesting that early steroid treatment could potentially prevent severe complications.

This phase Ib study found that combining pegylated liposomal doxorubicin and pembrolizumab was well-tolerated and effective, with durable antitumor responses and a median survival of over two years in heavily pretreated ER-positive metastatic breast cancer patients.

In this phase 1B study, patients with ER-positive/HER2-negative metastatic breast cancer receiving combined pegylated liposomal doxorubicin and pembrolizumab had a disease control rate of 67% with responses lasting a median of 11 months; the treatment was well tolerated and showed potential for extended use.

In this study, 37.5% of patients with nodal or metastatic cutaneous melanoma treated with immune checkpoint inhibitors developed skin adverse events, primarily low-grade rashes, vitiligo, and other dermatological symptoms, occurring mainly after 10 weeks of treatment.